Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. - Wikidata - wikimedia - TriplyDB

Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.

Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.

http://www.wikidata.org/entity/Q33898080

about

Erlotinib for advanced pancreatic cancer Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.Effects of arginine-glycine-aspartic acid peptide-conjugated quantum dots-induced photodynamic therapy on pancreatic carcinoma in vivo.Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma Pancreatic cancer genomics: where can the science take us?Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience SU11274 suppresses proliferation and motility of pancreatic cancer cells.Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines.Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer.Meta-analyses of treatment standards for pancreatic cancer.Epidemiology Characteristics, Methodological Assessment and Reporting of Statistical Analysis of Network Meta-Analyses in the Field of Cancer.Nanoformulations for therapy of pancreatic and liver cancers.The lymphatic system and pancreatic cancer.Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.Safety of palliative chemotherapy in advanced pancreatic cancer.Replication-competent adenoviruses with the type 35-derived fiber-knob region achieve reactive oxygen species-dependent cytotoxicity and produce greater toxicity than those with the type 5-derived region in pancreatic carcinoma.Surgical strategies and novel therapies for locally advanced pancreatic cancer.Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma.1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study.Clinical Trials in Pancreatic Cancer: A Long Slog."HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer.A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers.Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.

P2860

Q24186983-34A390D3-AD49-40D0-B800-ECD81BDB49B1 Q26828959-B138492D-120E-4AF6-AB6D-AFE5F84AB274 Q30315797-3F4C5665-5BCE-4A16-AA43-CE9BCFF3714C Q33421322-6D1FB073-94A0-462F-8BE1-71B43909E56A Q33442676-7641FA4D-B20A-4A7B-8C4E-0C912BB2B566 Q33553685-FDE94BAE-29C6-41D6-9287-05764C39473F Q33751227-9A40A4AF-E4BB-440B-A842-D1B4BD38635D Q34447458-B0EBA45D-FCB1-483F-ADA6-502BF966BB90 Q34537580-519E4241-7F2E-40B6-839E-B5C31A262846 Q35781556-12446882-FB2E-4622-B701-EB3CBC73670A Q35944581-5D5D831D-ED63-4584-B7E4-68401686282A Q36384541-A176C821-BA3A-4FF4-99A7-D92B3AB2527E Q36525403-693D1338-1D12-48A6-8634-3E8CEAF14725 Q36563900-3D9D1DCE-BD0B-459C-A2EC-29E60BA5BF2E Q36640493-893B5F6B-03DE-4531-BC24-978155F80E83 Q37416900-5184E9D6-8C25-449A-AF2E-63C5097C9FBD Q38495105-58742FB9-4248-4CF3-AC0D-1211B0C54604 Q38689578-9E49CA37-1FB8-4974-B4D4-6E06AB887B31 Q38760434-EC4328D8-2C66-4A56-B8C2-A8FDDA9BE70D Q38806041-46221EFD-D071-4A36-8F8B-B085DABFCA7B Q38835086-D0085F01-00E4-4AEA-9176-818EE9D21129 Q39312912-DA062332-11E5-4F4F-B4A5-C503B0C49DA5 Q40922213-153B0ED7-0219-4D77-8D43-D5717B767AFB Q41598639-5DA1D5CE-0C34-4CA4-BDE0-3E4B9AF14499 Q41958401-FD2CA808-B1ED-4F39-A1AD-4C2ADF4C2F9D Q47095955-78B3A807-D8E0-47AA-8CD7-750A0A8C91B5 Q47107002-84C2DC44-5610-45BF-9110-1BB015A528BB Q48293161-92C28197-882B-4B4C-BF98-8FADD04F64A6 Q50271158-7815CAE3-8F4A-490E-9E8F-221339293818 Q54112415-FF94843C-BFD6-4DB7-B910-1A47A7C87739 Q55381776-FC123A7E-FF9D-4082-AF39-BD8C16224539

P2860

Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.

http://www.wikidata.org/entity/Q33898080

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Chemotherapy regimens for adva ...... iew and network meta-analysis.

@ast

Chemotherapy regimens for adva ...... iew and network meta-analysis.

@en

type

label

Chemotherapy regimens for adva ...... iew and network meta-analysis.

@ast

Chemotherapy regimens for adva ...... iew and network meta-analysis.

@en

prefLabel

Chemotherapy regimens for adva ...... iew and network meta-analysis.

@ast

Chemotherapy regimens for adva ...... iew and network meta-analysis.

@en

P1433

Q33898080-B6F0D568-CB86-4E03-9A48-634C7BA52C95

P1476

Q33898080-7E7CF0CD-5D73-4983-8FB0-BFEDDE481E9F

P2093

Q33898080-1983B424-38E1-458E-B3B8-AB2ADFD8D063

Q33898080-4B389783-3E00-4681-B260-88078ED1B548

Q33898080-5B000FEE-A360-4456-B936-3271503ADE34

Q33898080-C0D63A69-5EC4-4533-8F66-76C6BB1F64BE

Q33898080-C6670DB6-4F27-45F2-9794-FF33CDCA2DAA

P275

Q33898080-D33E5DB2-8563-4047-BAD8-0C1856EC008B

P2860

Q33898080-030CB727-2123-48D5-AD59-5FF6FCB0D458

Q33898080-077EE93B-7FC2-413B-AD75-FA0267884A4F

Q33898080-0A2AFCE9-D691-461F-AED3-9F3A5F5AC206

Q33898080-1567E676-C4EE-4F20-9BE7-332537DFDEE5

Q33898080-1623BF2C-E069-405C-B052-61E5A9926D3D

Q33898080-1BDE00D2-DAE2-4830-A21D-5DA7BFBAA1E7

Q33898080-24509A27-1F32-47B3-A108-D0D155150A0C

Q33898080-273E2DFD-0951-47E3-AFCB-0BBF0B343B83

Q33898080-32DAA9A1-5431-4EFD-8A89-9E543C7903D8

Q33898080-39635508-39EC-4493-AFB4-E2EDC1DFA0B2

P2888

Q33898080-77A42141-62AE-4B48-98B4-DF0719829D93

P304

Q33898080-F53A1B38-CD68-4CF4-A4B8-C2E5D2C20BFB

P31

Q33898080-531F4DF1-179B-4897-83CC-0A5746700AF2

Q33898080-95afdb19-e305-4e2c-9018-51c6d3c93b98

Q33898080-A283C34C-C7D4-4F37-AAF5-C2AAB3447904

P356

Q33898080-0A31B5A5-3B41-4AB9-BD28-A226CBD55FE4

P407

Q33898080-5EC59A6C-2036-4E48-88BF-C139521E8DC9

P478

Q33898080-C0778344-30AA-4739-A6E6-250308CAE03D

P5008

Q33898080-133D2B9B-156A-4FF7-BECA-22BAE2A98FC2

P577

Q33898080-A03F3DE0-5618-40B6-B57C-EBB92DD3D4DC

P5875

Q33898080-05F15484-CE55-47B4-A372-709815C85369

P6179

Q33898080-71BF8751-884A-4E9B-AAE7-509E70B817FA

P698

Q33898080-6BC1C898-1333-473F-B6BC-D65CEDB92799

P921

Q33898080-0FBDCA62-24FC-4EBA-A8D7-2A2458ECB755

Q33898080-793EE17D-AD7C-4BFB-A7E7-2ADE55B5F63D

Q33898080-AA55EF65-467F-4D02-B6CA-A06EF6BF7EBA

P932

Q33898080-E137B9F4-B2FF-4C9B-A1EA-41D6ECDC8F40

P356

1471-2407-14-471

P1433

P1476

Chemotherapy regimens for adva ...... iew and network meta-analysis.

@en

P2093

Christopher Cameron

http://www.w3.org/2001/XMLSchema#string

Derek J Jonker

http://www.w3.org/2001/XMLSchema#string

George A Wells

http://www.w3.org/2001/XMLSchema#string

Gillian K Gresham

http://www.w3.org/2001/XMLSchema#string

Sharlene Gill

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Analysis of mortality rates for pancreatic cancer across the world

Indirect comparisons of competing interventions

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Systematic reviews in health care: Assessing the quality of controlled clinical trials

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.

Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data.

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.

P2888

1471-2407-14-471

P304

471

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-14-471

http://www.w3.org/2001/XMLSchema#string

P407

P478

14

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2014-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263512881

http://www.w3.org/2001/XMLSchema#string

P6179

1026098787

http://www.w3.org/2001/XMLSchema#string

P698

24972449

http://www.w3.org/2001/XMLSchema#string

P921

pancreatic cancer

pancreatic neoplasm

P932

4097092

http://www.w3.org/2001/XMLSchema#string